OClawVPS.com
Edit

PBM Capital Group

https://www.pbmcap.com
Last activity: 24.09.2024
Active
Invests in categories: ProductMedtechPlatformDrugHealthTechBioTechEngineeringScienceDevelopmentManufacturing
Portfolio
11
Persons
3
Mentions
8
Employees: 1-10
Investment Stage: Series B

Portfolio 11

DateNameWebsiteTotal RaisedLocation
31.12.2022SalioGen T...saliogen.com$115MUnited Sta...
04.01.2019Candel The...candeltx.com$51.2MUnited Sta...
-Xalud Ther...xaludthera.com$30MUnited Sta...
-Taysha Gen...tayshagtx.com$125MUnited Sta...
-Acumen Pha...acumenpharm.com$160MUnited Sta...
-Verrica Ph...verrica.com$180MUnited Sta...
-ARCHERDXarcherdx.com$150MUnited Sta...
-LEXEO Ther...lexeotx.com$180MUnited Sta...
-Dova Pharm...dova.com$75MUnited Sta...
-Enzymatics...enzymatics.com-United Sta...
Show more

Persons 3

DateFirst NameLast NameTitleLinkedInLocation
-JoePedersenPartner-
-StevenM. GoldmanManaging P...-
-JaysonRiegerManaging P...-

Mentions in press and media 8

DateTitleDescription
14.06.2022PBM Capital Rx raises $106M; Virtual surgery platform Proximie scores $80MPhoto: Proximie
31.08.2021Digital health news, funding roundup in the prior week; August 30Headspace's resilience brand and Ginger's clinical heft create mental health powerhouse Bambi Francisco Roizen sits down with Russ Glass, CEO of newly-formed Headspace Health, the combination of Ginger, a provider of on-demand coaching, the...
25.08.2021Daily funding roundup - August 24th, 2021Bridge to Life raised $56M; Covera Health landed $25M; Equum Medical secured $20M Ramp: Ramp is a New York-based corporate card and expense management platform. Ramp has raised $300 million in Series C funding. Founders Fund led the round, ...
04.01.2019PBM Capital Group Leads $28.7M Series B for Candel TherapeuticsAUBURNDALE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Candel Therapeutics, a clinical-stage biotechnology company developing novel cancer immunotherapy therapeutics, today announced the closing of a $28.7 million Series B financing led by PB...
04.01.2019PBM Capital Group Leads $28.7M Series B for Candel TherapeuticsAUBURNDALE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Candel Therapeutics, a clinical-stage biotechnology company developing novel cancer immunotherapy therapeutics, today announced the closing of a $28.7 million Series B financing led by PB...
06.01.2017Dova Pharmaceuticals Announces Hiring of CEO and Presentation at the 35th Annual J.P. Morgan Healthcare ConferenceCHARLOTTESVILLE, Va.–(BUSINESS WIRE)–January 6, 2017– Dova Pharmaceuticals, Inc., a clinical, late-stage company, having recently completed enrollment in two global, pivotal Phase 3 trials, is pleased to announce the appointment of its new ...
25.04.2014Gene therapy for spinal muscular atrophy secures funding to begin clinical trialsThe company’s approach is to deliver functioning copies of the SMN gene to cells so they can produce adequate SMN proteins. It does that using a viral vector licensed from the company ReGenX. The upcoming trial will enroll nine infants with...
-Gene therapy for spinal muscular atrophy secures funding to begin clinical trialsA Dallas biotech startup has raised money to begin clinical trials for what it hopes could be a treatment for the top genetic cause of infant mortality. AveXis is developing a viral gene therapy for infants with spinal muscular atrophy. Wit...

Reviews 0

Sign up to leave a review

Sign up Log In